ot) 2x Approvals + Profitability in 2012Nuvo is definitely one of the most undervalued stock in the Biotech Sector . Nuvo is a unknown Gem thats the only problem with this Goldmine but this will change soon with a Nasdaq or Amex listing which is planned for mid year .
Nuvo has already 2 Products (Pennsaid +Synera) on the Market .The next Product (Pliaglis) awaiting US and EU approval which will happen by mid 2012 .Nuvo will get $ 8 M milestone payment upon EU launch from their Partner Galderma who holds the worldwide rights for Pliaglis .(MORE INFOS IN THEIR PRESENTATION LINK BELOW)
Nuvo will be profitable by late 2012 or early 2013 the future looks definitely very good for this Goldmine .
Market cap of $ 36 M is really a PURE GIFT for a Biotech Company which has almost 3 Products on the Market and $ 18 M in Cash .
Fantastic entry point at this HUGE bargain level .Patience will payoff big time here .GLTA
MY TARGET:
.50++ WITHIN 12 MONTHS
Nuvo Research (NRI.TO)
Market Cap : $ 39.4 M
Cash: $ 18.1 M
Price 0.07 $
NO DEBT
Presentation Jan 2012..A MUST READ !!!
https://www.nuvoresearch.com/investors/documents/presentations/2012-01-04%20Nuvo%
20IR%20Presentation%20January_2012.pdf
Insider Activity
https://canadianinsider.com/node/7?menu_tickersearch=nri
UPCOMING MILESTONES 2012 :
Growing Pennsaid U.S. sales = higher royalty revenue
Covidien sNDA for Pennsaid 2%
Pliaglis approval and launch in the U.S. and E.U. = new royalty
revenue and milestone payments ( 15% royalties + $8 M milestone upon EU launch )
Relaunch Synera in the U.S. and expand in the E.U.
Announce action plan for WF10 development
Corporate Profile
Nuvo Research Inc. is a publicly traded (TSX:NRI), Canadian specialty pharmaceutical company, headquartered in Mississauga, Ontario. The Company is building a portfolio of products for the treatment of pain through internal research and development and by in-licensing and acquisition.
The Company's Pain Group, located in West Chester, Pennsylvania, is focused on the development and commercialization of topically delivered pain products. The Company's product portfolio includes Pennsaid®, Pliaglis® and Synera®.
Pennsaid, a topical NSAID, is used to treat the signs and symptoms of OA of the knee(s). Pennsaid is sold in the United States by Mallinckrodt Inc., a Covidien company (NYSE: COV), in Canada by Paladin Labs Inc. (TSX:PLB) and in several European countries.
Pliaglis is a topical local anesthetic cream, which is FDA-approved to provide topical local analgesia for superficial dermatological procedures. The Company has licensed worldwide marketing rights to Pliaglis to Galderma Pharma S.A., a global specialty pharmaceutical company focused on dermatology.
Synera is a topical patch that combines lidocaine, tetracaine and heat, approved in the United States to provide local dermal analgesia for superficial venous access and superficial dermatological procedures and in Europe, for surface anaesthesia of normal intact skin. Nuvo currently markets Synera in the United States and its licensing partner, EuroCept International B.V., has initiated a pan-European launch of Synera (under the name Rapydan) in several European countries.
Through its subsidiary, Nuvo Research GmbH, based in Leipzig, Germany, the Company is also developing the compound WF10, for the treatment of immune related diseases